Antidepressant Market size was valued at US$ 15.83 Bn. in 2022 and the total revenue is expected to grow at 2.92 % through 2023 to 2029, reaching nearly US$ 19.37 Bn.
Antidepressant Market Overview:Antidepressants are drugs that are prescribed to treat major depression, mental illnesses, chronic fatigue, and alcoholism. Jaw clenching, weight gain, nausea, migraines, loss of libido, and psychological blunting are some of the most common antidepressant side effects. When taken by children, teenagers, and young adults, there is a slight increase in the risk of suicide ideation and behaviour. After discontinuing any antidepressant, discontinuation syndrome, which mimics recurrent depression, might develop. In the medical profession, there is disagreement about how much of the reported effects of antidepressants may be attributed to the placebo effect, with others saying that there is no impact beyond it. The majority of studies on whether antidepressant medicines work is conducted on patients with severe symptoms, a population with far lower placebo responses, therefore the findings cannot be applied to the broader population.To know about the Research Methodology :- Request Free Sample Report
Antidepressant Market Dynamics:The market is expected to grow as the number of clinical studies increases, resulting in more unique medication approvals. Market leaders and government agencies are working hard to make products more accessible to people in medium and low income levels. Additionally, strong industry engagement in the development of antidepressant medications, as well as a large number of late-stage clinical studies, is likely to accelerate market growth. Also, increasing use of artificial intelligence (AI) and machine learning in depression diagnosis will improve doctors' capacity to prescribe accurate drugs. Antidepressant medicine demand will rise as the prevalence of depression and related mental health problems rises. According to the World Health Organization, almost 40 million individuals in Europe suffer from depressive disorders, accounting for around 4.3 percent of the total population. Furthermore, the Centers for Disease Control and Prevention estimates that around 16 million adult Americans suffer from depression each year. Antidepressant medication demand will rise as a result of such a big patient population. Also, according to the World Health Organization, three out of every four persons suffering from depression do not receive adequate therapy. To business executives, this shows the market's potential for growth. Chronic diseases are becoming more widespread, adding to the psychological burden on patients by demanding long-term medications, which adds to the financial cost, especially in low-income countries. Depression affects 76 percent to 85 percent of all patients in low- and middle-income nations, according to the World Health Organization. During the COVID-19 pandemic, the antidepressant medicine business continued to rise in income. COVID-19's emergence has sparked one of the largest employment losses in various industries, resulting in economic instability. Social isolation and movement limitations, in addition to economic uncertainty, have led in despair and anxiety among the populace.
Antidepressant Market Segment Analysis:Based on the Product, the global Antidepressant market is sub-segmented into Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-norepinephrine reuptake Inhibitors, Monoamine oxidase inhibitors and Others. The Tricyclic Antidepressants segment held the largest market share of xx% in 2022. Patients with severe depression (MDD), post-traumatic stress disorder (PTSD), panic disorder, and other mental health conditions may benefit from tricyclic antidepressants. As a consequence of its use in a variety of ailments, sales have surged. There has been a rise in acceptability as well. During the forecast period, opioid-related illness therapy, stress management, and chronic disease management will all have an influence on market segment growth. Based on the Depression Disorder, the global Antidepressant market is sub-segmented into Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder and Others. The Major Depressive Disorder segment held the largest market share of xx% in 2022. The high incidence rate in industrialized countries is a major driver of the segment's growth. The category is estimate to grow at a large rate during the forecast period as a result of high stress levels induced by several socioeconomic variables and the strong purchasing power of this age group.
Regional Insights:North America held the largest market share of xx% in 2022. The increase in the elderly population in the United States is expected to create more opportunities for market participants in the region. According to the American Anxiety and Depression Association, facts and statistics, anxiety disorder is one of the most common mental illnesses in the United States, affecting approximately 40 million American adults each year, accounting for 18.1% of the total population of the United States. In addition, more than 16.1 million American adults suffer from major depression each year, and women are more common than men. Asia Pacific is expected to grow at a highest CAGR of xx% in the global Antidepressant market during the forecast period. The rising frequency of chronic illnesses has added to the psychological toll. According to the World Health Organization, the Asia area accounted for roughly half of the total population suffering from depression. For foreign industrial participants, these patients provide commercial growth potential. Additionally, with government backing, rising healthcare spending and availability of mental health treatment across the area would boost product sales. As a result, the regional growth will be aided by the existence of market participants with a big patient pool. The objective of the report is to present a comprehensive analysis of the global Antidepressant Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The reports also helps in understanding the global Antidepressant Market dynamic, structure by analyzing the market segments and project the global Antidepressant Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the global Antidepressant Market make the report investor’s guide.
Global Antidepressant Market Scope: Inquire before buying
Antidepressant Market Report Coverage Details Base Year: 2022 Forecast Period: 2023-2029 Historical Data: 2018 to 2022 Market Size in 2022: US $ 15.83 Bn. Forecast Period 2023 to 2029 CAGR: 2.92 % Market Size in 2029: US $ 19.37 Bn. Segments Covered: by Product Tricyclic Antidepressants Selective Serotonin Reuptake Inhibitors Serotonin-norepinephrine reuptake Inhibitors Monoamine oxidase inhibitors Others by Depression Disorder Major Depressive Disorder Obsessive-Compulsive Disorder Generalized Anxiety Disorder Panic Disorder Others by Distribution Channel Hospital Pharmacy Retail Pharmacy
Global Antidepressant Market, by Region:Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) North America (United States, Canada and Mexico) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)
Key Players:1. AstraZeneca plc 2. Eli Lilly and Company 3. Forest Laboratories 4. GlaxoSmithKline plc 5. H. Lundbeck A/S 6. Johnson & Johnson 7. Merck & Co., Inc. 8. Pfizer, Inc. 9. Sanofi S.A. 10. Allergan PLC 11. Sun Pharmaceuticals Pvt Ltd. 12. Alkermes Plc 13. Bristol Myers Squibb Co 14. Teva Pharmaceutical Industries Ltd. 15. Takeda Pharmaceutical Co. Ltd. 16. Novartis AG 17. Opko Health
Frequently Asked Questions:1] What segments are covered in Antidepressant Market report? Ans. The segments covered in Antidepressant Market report are based on Product, Depression Disorder, and Distribution Channel. 2] Which region is expected to hold the highest share in the Antidepressant Market? Ans. North America is expected to hold the highest share in the global Antidepressant Market. 3] What is the market size of global Antidepressant Market by 2029? Ans. The market size of global Antidepressant Market is expected to reach US $ 19.37 Bn. by 2029. 4] Who are the top key players in the Antidepressant Market? Ans. AstraZeneca plc, Eli Lilly and Company, Forest Laboratories, GlaxoSmithKline plc, H. Lundbeck A/S and Johnson & Johnson are the top key players in the global Antidepressant Market. 5] What was the market size of Antidepressant Market in 2022? Ans. The market size of Antidepressant Market in 2022 was US $ 15.83 Bn.
1. Global Antidepressant Market: Research Methodology 2. Global Antidepressant Market: Executive Summary 2.1 Market Overview and Definitions 2.1.1. Introduction to Global Antidepressant Market 2.2. Summary 2.1.1. Key Findings 2.1.2. Recommendations for Investors 2.1.3. Recommendations for Market Leaders 2.1.4. Recommendations for New Market Entry 3. Global Antidepressant Market: Competitive Analysis 3.1 MMR Competition Matrix 3.1.1. Market Structure by region 3.1.2. Competitive Benchmarking of Key Players 3.2 Consolidation in the Market 3.2.1 M&A by region 3.3 Key Developments by Companies 3.4 Market Drivers 3.5 Market Restraints 3.6 Market Opportunities 3.7 Market Challenges 3.8 Market Dynamics 3.9 PORTERS Five Forces Analysis 3.10 PESTLE 3.11 Regulatory Landscape by region • North America • Europe • Asia Pacific • The Middle East and Africa • Latin America 3.12 COVID-19 Impact 4. Global Antidepressant Market Segmentation 4.1 Global Antidepressant Market, by Product (2022-2029) • Tricyclic Antidepressants • Selective Serotonin Reuptake Inhibitors • Serotonin-norepinephrine reuptake Inhibitors • Monoamine oxidase inhibitors • Others 4.2 Global Antidepressant Market, by Depression Disorder (2022-2029) • Major Depressive Disorder • Obsessive-Compulsive Disorder • Generalized Anxiety Disorder • Panic Disorder • Others 4.3 Global Antidepressant Market, by Distribution Channel (2022-2029) • Hospital Pharmacy • Retail Pharmacy 5. North America Antidepressant Market(2022-2029) 5.1 Global Antidepressant Market, by Product (2022-2029) • Tricyclic Antidepressants • Selective Serotonin Reuptake Inhibitors • Serotonin-norepinephrine reuptake Inhibitors • Monoamine oxidase inhibitors • Others 5.2 Global Antidepressant Market, by Drug Class (2022-2029) • Major Depressive Disorder • Obsessive-Compulsive Disorder • Generalized Anxiety Disorder • Panic Disorder • Others 5.3 Global Antidepressant Market, by Distribution Channel (2022-2029) • Hospital Pharmacy • Retail Pharmacy 5.4 North America Antidepressant Market, by Country (2022-2029) • United States • Canada • Mexico 6. Asia Pacific Antidepressant Market (2022-2029) 6.1. Asia Pacific Antidepressant Market, by Product (2022-2029) 6.2. Asia Pacific Antidepressant Market, by Depression Disorder (2022-2029) 6.3. Asia Pacific Antidepressant Market, by Distribution Channel (2022-2029) 6.4. Asia Pacific Antidepressant Market, by Country (2022-2029) • China • India • Japan • South Korea • Australia • ASEAN • Rest Of APAC 7. Middle East and Africa Antidepressant Market (2022-2029) 7.1 Middle East and Africa Antidepressant Market, by Product (2022-2029) 7.2. Middle East and Africa Antidepressant Market, by Depression Disorder (2022-2029) 7.3. Middle East and Africa Antidepressant Market, by Distribution Channel (2022-2029) 7.4. Middle East and Africa Antidepressant Market, by Country (2022-2029) • South Africa • GCC • Egypt • Nigeria • Rest Of ME&A 8. Latin America Antidepressant Market (2022-2029) 8.1. Latin America Antidepressant Market, by Product (2022-2029) 8.2. Latin America Antidepressant Market, by Depression Disorder (2022-2029) 8.3. Latin America Antidepressant Market, by Distribution Channel (2022-2029) 8.4 Latin America Antidepressant Market, by Country (2022-2029) • Brazil • Argentina • Rest Of Latin America 9. European Antidepressant Market (2022-2029) 9.1. European Antidepressant Market, by Product (2022-2029) 9.2. European Antidepressant Market, by Depression Disorder (2022-2029) 9.3. European Antidepressant Market, by Distribution Channel (2022-2029) 9.4. European Antidepressant Market, by Country (2022-2029) • UK • France • Germany • Italy • Spain • Sweden • Austria • Rest Of Europe 10. Company Profile: Key players 10.1. AstraZeneca plc 10.1.1. Company Overview 10.1.2. Financial Overview 10.1.3. Global Presence 10.1.4. Capacity Portfolio 10.1.5. Business Strategy 10.1.6. Recent Developments 10.2. Eli Lilly and Company 10.3. Forest Laboratories 10.4. GlaxoSmithKline plc 10.5. H. Lundbeck A/S 10.6. Johnson & Johnson 10.7. Merck & Co., Inc. 10.8. Pfizer, Inc. 10.9. Sanofi S.A. 10.10. Allergan PLC 10.11. Sun Pharmaceuticals Pvt Ltd. 10.12. Alkermes Plc 10.13. Bristol Myers Squibb Co 10.14. Teva Pharmaceutical Industries Ltd. 10.15. Takeda Pharmaceutical Co. Ltd. 10.16. Novartis AG 10.17. Opko Health